广告
加载中

阿里健康与默克中国达成慢病合作:科普、续方、随访三端落地

亿邦动力 2026-10-30 15:45
亿邦动力 2026/10/30 15:45

邦小白快读

EN
全文速览

总1

这次合作的核心是把慢病用药从单次购药转向长期管理。

1.阿里健康与默克中国围绕甲状腺、糖尿病、心血管等慢病,在患者教育、在线续方和长期用药管理三方面合作。

2.患者可获得数字化权威科普与规范用药指导,在线续方与履约流程优化,以及用药提醒、随访和药师咨询。

总2

文章给出几组可用数据和能力信息。

1.中国甲状腺疾病患者约2.1亿,总体患病率约35.6%,知晓率26%,治疗率不足5%;糖尿病患者1.48亿,知晓率36.7%,治疗率32.9%,血糖控制率16.5%。

2.阿里健康已构建“预防—诊疗—用药—管理”服务链路,具备在线复诊开方、药师审方和分钟级配送能力。

总3

对普通读者的实操提示是重视连续管理。

1.慢病用药以年为单位,需要复查、续方、配送的持续支持,而非单次购药。

2.2025年中国线上问诊市场规模超过750亿元,线上药品渗透率仍处低位。

总1

合作对品牌营销与渠道建设的启示集中在慢病长期服务。

1.阿里健康与默克中国签署战略合作备忘录,围绕甲状腺、糖尿病、心血管等慢病开展患者教育、在线续方和长期用药管理。

2.默克创建于1668年,医药健康业务在中国覆盖辅助生殖、肿瘤、心血管与代谢、神经病学与免疫学等领域,目前经营16款药品;南通制药基地2017年投用,是默克全球第二大制药基地,年产量可达100亿片。

总2

用户行为与消费趋势显示慢病管理有持续服务需求。

1.甲状腺等慢病用药以年为单位,患者需要复查、续方、配送的持续支持,而非单次购药。

2.中国甲状腺疾病患者约2.1亿,知晓率26%,治疗率不足5%;糖尿病患者1.48亿,知晓率36.7%,治疗率32.9%,血糖控制率16.5%。

总3

品牌渠道可从单次药品销售延伸到全链路服务。

1.阿里健康以平台流量、药品履约与数字化工具,将业务从单一药品销售延伸至覆盖预防、诊疗、用药、管理的全链路服务。

2.2026年以来阿里健康与诺华、阿斯利康、腾瑞制药、派格生物等药企协同提速。

总1

这次合作给出慢病市场的合作方式与增长机会。

1.阿里健康与默克中国在甲状腺、糖尿病、心血管等慢病领域合作,落地患者教育、在线续方和长期用药管理三端。

2.合作内容包括数字化权威科普与规范用药指导、优化在线续方与履约流程、通过用药提醒、随访和药师咨询把以年为单位的用药纳入连续管理。

总2

市场数据提示需求空间,也提示经营风险。

1.中国甲状腺疾病患者约2.1亿,总体患病率约35.6%,知晓率26%,治疗率不足5%;糖尿病患者1.48亿,知晓率36.7%,治疗率32.9%,血糖控制率16.5%。

2.2025年中国线上问诊市场规模超过750亿元,但线上药品渗透率仍处低位,未来3至5年市场将发生结构性变化。

总3

可学习点是连续服务与药企协同。

1.阿里健康已构建“预防—诊疗—用药—管理”服务链路,具备在线复诊开方、药师审方和分钟级配送能力。

2.2026年以来其与诺华、阿斯利康、腾瑞制药、派格生物等合作提速,显示慢病管理赛道的合作机会。

总1

文章对工厂的直接信息集中在默克制药基地的生产能力。

1.默克创建于1668年,总部位于德国达姆施塔特,业务覆盖生命科学、医药健康和电子科技三大领域。

2.位于南通的制药基地2017年投入使用,是默克全球第二大制药基地,年产量可达100亿片;其医药健康业务在中国经营16款药品,覆盖辅助生殖、肿瘤、心血管与代谢、神经病学与免疫学等领域。

总2

慢病合作带来产品供应与商业机会启示。

1.合作围绕甲状腺、糖尿病、心血管等慢病,涉及患者教育、在线续方和长期用药管理,药品需要持续稳定供应。

2.患者需要复查、续方、配送的持续支持,而非单次购药,长期用药管理以年为单位。

总3

数字化和电商启示是接入全链路服务。

1.阿里健康具备在线复诊开方、药师审方和分钟级配送能力,并构建“预防—诊疗—用药—管理”服务链路。

2.工厂端可关注与平台履约、用药提醒、随访和药师咨询等服务衔接。

总1

慢病数字化服务的客户痛点清晰。

1.中国甲状腺疾病患者约2.1亿,总体患病率约35.6%,知晓率26%,治疗率不足5%;糖尿病患者1.48亿,知晓率36.7%,治疗率32.9%,血糖控制率16.5%。

2.甲状腺等慢病用药以年为单位,患者需要复查、续方、配送的持续支持,而非单次购药。

总2

合作给出三端解决方案。

1.以数字化方式提供甲状腺等慢病的权威科普与规范用药指导。

2.优化在线续方与履约流程,保障患者持续、稳定获得所需药品。

3.通过用药提醒、随访和药师咨询,将以年为单位的用药纳入连续管理。

总3

行业趋势与能力要求值得关注。

1.2025年中国线上问诊市场规模超过750亿元,线上药品渗透率仍处低位,未来3至5年市场将发生结构性变化。

2.阿里健康已具备在线复诊开方、药师审方和分钟级配送能力,并与默克共同开展管理案例研究。

总1

药企对平台的需求集中在患者教育、续方履约和长期管理。

1.阿里健康与默克中国合作,围绕甲状腺、糖尿病、心血管等慢病,在患者教育、在线续方和长期用药管理方面开展合作。

2.双方将以各自慢病服务与疾病治疗经验为基础,共同开展管理案例研究。

总2

平台最新做法是构建全链路服务能力。

1.阿里健康自营事业部表示,已构建“预防—诊疗—用药—管理”服务链路,具备在线复诊开方、药师审方和分钟级配送能力。

2.合作落地数字化权威科普与规范用药指导、优化在线续方与履约流程、用药提醒、随访和药师咨询。

总3

招商合作与运营风向值得平台商关注。

1.2026年以来阿里健康与诺华就慢性荨麻疹、与阿斯利康聚焦呼吸心血管代谢全周期管理,与腾瑞制药、派格生物围绕GLP-1相关药物探索院外服务。

2.线上药品渗透率仍处低位,未来3至5年市场将发生结构性变化,需围绕以年为单位的连续管理做运营。

总1

产业新动向是药企与数字健康平台加速布局慢病管理。

1.阿里健康与默克中国签署战略合作备忘录,围绕甲状腺、糖尿病、心血管等慢病,在患者教育、在线续方和长期用药管理方面合作。

2.2026年以来阿里健康先后与诺华、阿斯利康、腾瑞制药、派格生物合作,显示药企与平台协同提速。

总2

研究可关注的新问题与数据。

1.中国甲状腺疾病患者约2.1亿,总体患病率约35.6%,知晓率26%,治疗率不足5%;糖尿病患者1.48亿,知晓率36.7%,治疗率32.9%,血糖控制率16.5%。

2.2025年中国线上问诊市场规模超过750亿元,线上药品渗透率仍处低位,未来3至5年市场将发生结构性变化。

总3

商业模式启示是从单次销售转向连续管理。

1.阿里健康依托平台流量、药品履约与数字化工具,将业务从单一药品销售延伸至覆盖预防、诊疗、用药、管理的全链路服务。

2.合作强调以年为单位的用药连续管理,并共同开展管理案例研究,可作为慢病数字化服务研究样本。

返回默认

声明:快读内容全程由AI生成,请注意甄别信息。如您发现问题,请发送邮件至 run@ebrun.com 。

我是 品牌商 卖家 工厂 服务商 平台商 研究者 帮我再读一遍。

Quick Summary

Summary 1

The core of this collaboration is to shift chronic-disease medication from one-off purchases to long-term management.

1. Alibaba Health and Merck China are collaborating on chronic diseases such as thyroid disorders, diabetes, and cardiovascular disease across three areas: patient education, online prescription renewal, and long-term medication management.

2. Patients can access authoritative digital education and standardized medication guidance, optimized online prescription-renewal and fulfillment processes, and medication reminders, follow-ups, and pharmacist consultations.

Summary 2

The article provides several usable data points and capability details.

1. China has about 210 million thyroid-disease patients, with an overall prevalence of about 35.6%, an awareness rate of 26%, and a treatment rate of less than 5%; diabetes patients number 148 million, with an awareness rate of 36.7%, a treatment rate of 32.9%, and a glycemic control rate of 16.5%.

2. Alibaba Health has built a service chain covering prevention, diagnosis, treatment, medication, and management, with capabilities for online follow-up consultations and prescribing, pharmacist prescription review, and minute-level delivery.

Summary 3

The practical takeaway for general readers is to prioritize continuous management.

1. Chronic-disease medication is measured in years and requires ongoing support for re-examinations, prescription renewal, and delivery, rather than one-off purchases.

2. In 2025, China's online consultation market exceeded RMB 75 billion, while online drug penetration remains low.

Summary 1

The implications of the collaboration for brand marketing and channel building center on long-term chronic-disease services.

1. Alibaba Health and Merck China signed a strategic cooperation memorandum covering patient education, online prescription renewal, and long-term medication management for chronic diseases such as thyroid disorders, diabetes, and cardiovascular disease.

2. Merck was founded in 1668. Its healthcare business in China covers assisted reproduction, oncology, cardiovascular and metabolic diseases, neurology and immunology, among other areas, and currently markets 16 drugs; its Nantong pharmaceutical plant began operations in 2017 and is Merck's second-largest pharmaceutical manufacturing site globally, with annual capacity of up to 10 billion tablets.

Summary 2

User behavior and consumption trends indicate sustained service demand for chronic-disease management.

1. Medication for chronic diseases such as thyroid disorders is measured in years, and patients need ongoing support for re-examinations, prescription renewal, and delivery rather than one-off purchases.

2. China has about 210 million thyroid-disease patients, with an awareness rate of 26% and a treatment rate of less than 5%; diabetes patients number 148 million, with an awareness rate of 36.7%, a treatment rate of 32.9%, and a glycemic control rate of 16.5%.

Summary 3

Brand channels can extend from one-off drug sales to full-chain services.

1. With platform traffic, drug fulfillment, and digital tools, Alibaba Health is extending its business from single-drug sales to full-chain services covering prevention, diagnosis, treatment, medication, and management.

2. Since 2026, Alibaba Health has accelerated collaboration with pharmaceutical companies including Novartis, AstraZeneca, Tengrui Pharmaceutical, and Pegbio.

Summary 1

The collaboration highlights partnership models and growth opportunities in the chronic-disease market.

1. Alibaba Health and Merck China are collaborating in chronic-disease areas such as thyroid disorders, diabetes, and cardiovascular disease, with implementation across patient education, online prescription renewal, and long-term medication management.

2. The collaboration includes authoritative digital education and standardized medication guidance, optimized online prescription-renewal and fulfillment processes, and the integration of year-long medication use into continuous management through medication reminders, follow-ups, and pharmacist consultations.

Summary 2

Market data indicate demand potential and operational risks.

1. China has about 210 million thyroid-disease patients, with an overall prevalence of about 35.6%, an awareness rate of 26%, and a treatment rate of less than 5%; diabetes patients number 148 million, with an awareness rate of 36.7%, a treatment rate of 32.9%, and a glycemic control rate of 16.5%.

2. In 2025, China's online consultation market exceeded RMB 75 billion, but online drug penetration remains low, and the market will undergo structural changes over the next three to five years.

Summary 3

Key lessons are continuous service and collaboration with pharmaceutical companies.

1. Alibaba Health has built a service chain covering prevention, diagnosis, treatment, medication, and management, with capabilities for online follow-up consultations and prescribing, pharmacist prescription review, and minute-level delivery.

2. Since 2026, its collaborations with Novartis, AstraZeneca, Tengrui Pharmaceutical, Pegbio, and others have accelerated, indicating partnership opportunities in the chronic-disease management sector.

Summary 1

The article's direct information for factories centers on the production capacity of Merck's pharmaceutical manufacturing site.

1. Merck was founded in 1668 and is headquartered in Darmstadt, Germany. Its business covers three areas: life sciences, healthcare, and electronics.

2. Its pharmaceutical plant in Nantong began operations in 2017 and is Merck's second-largest pharmaceutical manufacturing site globally, with annual capacity of up to 10 billion tablets; its healthcare business in China markets 16 drugs covering assisted reproduction, oncology, cardiovascular and metabolic diseases, neurology and immunology, among other areas.

Summary 2

The chronic-disease collaboration offers implications for product supply and commercial opportunities.

1. The collaboration focuses on chronic diseases such as thyroid disorders, diabetes, and cardiovascular disease and involves patient education, online prescription renewal, and long-term medication management, requiring sustained and stable drug supply.

2. Patients need ongoing support for re-examinations, prescription renewal, and delivery rather than one-off purchases, and long-term medication management is measured in years.

Summary 3

The digital and e-commerce implication is to connect with full-chain services.

1. Alibaba Health has capabilities for online follow-up consultations and prescribing, pharmacist prescription review, and minute-level delivery, and has built a service chain covering prevention, diagnosis, treatment, medication, and management.

2. Factories can focus on integrating with platform fulfillment, medication reminders, follow-ups, and pharmacist consultations.

Summary 1

Customer pain points for digital chronic-disease services are clear.

1. China has about 210 million thyroid-disease patients, with an overall prevalence of about 35.6%, an awareness rate of 26%, and a treatment rate of less than 5%; diabetes patients number 148 million, with an awareness rate of 36.7%, a treatment rate of 32.9%, and a glycemic control rate of 16.5%.

2. Medication for chronic diseases such as thyroid disorders is measured in years, and patients need ongoing support for re-examinations, prescription renewal, and delivery rather than one-off purchases.

Summary 2

The collaboration offers a three-part solution.

1. Provide authoritative digital education and standardized medication guidance for chronic diseases such as thyroid disorders.

2. Optimize online prescription-renewal and fulfillment processes to ensure patients can consistently and reliably obtain needed drugs.

3. Through medication reminders, follow-ups, and pharmacist consultations, integrate year-long medication use into continuous management.

Summary 3

Industry trends and capability requirements merit attention.

1. In 2025, China's online consultation market exceeded RMB 75 billion, while online drug penetration remains low, and the market will undergo structural changes over the next three to five years.

2. Alibaba Health already has capabilities for online follow-up consultations and prescribing, pharmacist prescription review, and minute-level delivery, and is conducting management case studies with Merck.

Summary 1

Pharmaceutical companies' demand for platforms centers on patient education, prescription-renewal fulfillment, and long-term management.

1. Alibaba Health and Merck China are collaborating on chronic diseases such as thyroid disorders, diabetes, and cardiovascular disease in patient education, online prescription renewal, and long-term medication management.

2. Based on their respective chronic-disease services and disease-treatment experience, the two parties will jointly conduct management case studies.

Summary 2

The platform's latest approach is to build full-chain service capabilities.

1. Alibaba Health's self-operated business unit said it has built a service chain covering prevention, diagnosis, treatment, medication, and management, with capabilities for online follow-up consultations and prescribing, pharmacist prescription review, and minute-level delivery.

2. The collaboration implements authoritative digital education and standardized medication guidance, optimized online prescription-renewal and fulfillment processes, medication reminders, follow-ups, and pharmacist consultations.

Summary 3

Partnership and operational trends deserve platform operators' attention.

1. Since 2026, Alibaba Health has worked with Novartis on chronic urticaria, with AstraZeneca on full-cycle management of respiratory, cardiovascular, and metabolic diseases, and with Tengrui Pharmaceutical and Pegbio on exploring out-of-hospital services around GLP-1-related drugs.

2. Online drug penetration remains low, and the market will undergo structural changes over the next three to five years, requiring operations centered on year-long continuous management.

Summary 1

The new industry development is the accelerated push by pharmaceutical companies and digital health platforms into chronic-disease management.

1. Alibaba Health and Merck China signed a strategic cooperation memorandum to collaborate on chronic diseases such as thyroid disorders, diabetes, and cardiovascular disease in patient education, online prescription renewal, and long-term medication management.

2. Since 2026, Alibaba Health has successively collaborated with Novartis, AstraZeneca, Tengrui Pharmaceutical, and Pegbio, showing acceleration in pharmaceutical-company/platform collaboration.

Summary 2

New research questions and data worth attention.

1. China has about 210 million thyroid-disease patients, with an overall prevalence of about 35.6%, an awareness rate of 26%, and a treatment rate of less than 5%; diabetes patients number 148 million, with an awareness rate of 36.7%, a treatment rate of 32.9%, and a glycemic control rate of 16.5%.

2. In 2025, China's online consultation market exceeded RMB 75 billion, while online drug penetration remains low, and the market will undergo structural changes over the next three to five years.

Summary 3

The business-model implication is a shift from one-off sales to continuous management.

1. Relying on platform traffic, drug fulfillment, and digital tools, Alibaba Health is extending its business from single-drug sales to full-chain services covering prevention, diagnosis, treatment, medication, and management.

2. The collaboration emphasizes year-long continuous medication management and joint management case studies, which can serve as a research sample for digital chronic-disease services.

Disclaimer: The "Quick Summary" content is entirely generated by AI. Please exercise discretion when interpreting the information. For issues or corrections, please email run@ebrun.com .

I am a Brand Seller Factory Service Provider Marketplace Seller Researcher Read it again.

【亿邦原创】日前,阿里健康与默克中国医药健康签署战略合作备忘录,双方将围绕甲状腺、糖尿病、心血管等慢病领域,在患者教育、在线续方和长期用药管理等方面开展合作。

公开资料显示,默克创建于1668年,总部位于德国达姆施塔特,业务覆盖生命科学、医药健康和电子科技三大领域。其医药健康业务在中国覆盖辅助生殖、肿瘤、心血管与代谢、神经病学与免疫学等治疗领域,目前在中国经营16款药品。位于南通的制药基地2017年投入使用,是默克全球第二大制药基地,年产量可达100亿片。

根据合作安排,双方将以各自在慢病服务与疾病治疗领域的经验为基础,共同开展管理案例研究,并为患者提供三方面服务:以数字化方式提供甲状腺等慢病的权威科普与规范用药指导;优化在线续方与履约流程,保障患者持续、稳定地获得所需药品;通过用药提醒、随访和药师咨询,将以年为单位的用药纳入连续管理。

阿里健康自营事业部总经理章泽表示,甲状腺等慢病用药以年为单位,患者需要的是复查、续方、配送的持续支持,而非单次购药;阿里健康已构建"预防—诊疗—用药—管理"服务链路,具备在线复诊开方、药师审方和分钟级配送能力。默克方面则表示,合作是其深耕中国数字健康领域的一步,希望让慢病管理触达更多患者。

行业数据方面,中国甲状腺疾病患者约2.1亿,总体患病率约35.6%,知晓率26%,治疗率不足5%。糖尿病患者1.48亿,知晓率36.7%,治疗率32.9%,血糖控制率16.5%。2025年中国线上问诊市场规模超过750亿元。章泽此前曾表示,线上药品渗透率仍处于低位,未来3至5年市场将发生结构性变化。

值得关注的是,这并非阿里健康首次涉足慢病管理领域的药企合作。2026年以来,其与药企的协同明显提速:3月与诺华就慢性荨麻疹达成数字化合作,与阿斯利康签约聚焦呼吸、心血管、代谢领域的全周期管理;7月与腾瑞制药、派格生物合作,围绕GLP-1相关药物探索院外服务。多年来,阿里健康持续加码慢病管理赛道,依托平台流量、药品履约与数字化工具,逐步将业务从单一药品销售延伸至覆盖预防、诊疗、用药、管理的全链路服务。

本文首发于 亿邦动力 官方网站

文章来源:亿邦动力

广告
微信
朋友圈

FAQ回顾

阿里健康与默克中国在慢病管理方面有哪些合作?

双方签署战略合作备忘录,围绕甲状腺、糖尿病、心血管等慢病领域,在患者教育、在线续方和长期用药管理方面合作。具体包括以数字化方式提供权威科普与规范用药指导,优化在线续方与履约流程,并通过用药提醒、随访和药师咨询,将按年使用的慢病用药纳入连续管理。

中国甲状腺疾病患者规模和治疗现状如何?

中国甲状腺疾病患者约2.1亿,总体患病率约35.6%,知晓率26%,治疗率不足5%。患者规模大,但疾病知晓率和治疗率仍较低,规范化科普、在线续方和长期随访对提升慢病管理效率具有现实需求。

慢病用药为什么需要在线续方和长期随访?

甲状腺等慢病用药以年为单位,患者需要的是复查、续方、配送的持续支持,而非单次购药。阿里健康已构建“预防—诊疗—用药—管理”服务链路,具备在线复诊开方、药师审方和分钟级配送能力;合作通过在线续方、用药提醒、随访和药师咨询实现连续管理。

阿里健康近年与哪些药企开展慢病管理合作?

2026年以来,阿里健康与默克中国围绕甲状腺、糖尿病、心血管等慢病合作;3月与诺华就慢性荨麻疹达成数字化合作,与阿斯利康签约聚焦呼吸、心血管、代谢领域全周期管理;7月与腾瑞制药、派格生物围绕GLP-1相关药物探索院外服务。

中国线上问诊市场规模和线上药品趋势如何?

2025年中国线上问诊市场规模超过750亿元。阿里健康章泽此前表示,线上药品渗透率仍处于低位,未来3至5年市场将发生结构性变化。阿里健康正依托平台流量、药品履约与数字化工具,将业务从单一药品销售延伸至预防、诊疗、用药、管理的全链路服务。

这么好看,分享一下?

朋友圈 分享

APP内打开

赞 +1
+1
微信好友 朋友圈 新浪微博 QQ空间
关闭
收藏成功
发送
/140 0